News
1 November, 2019

Barcelona Liver Bioservices announces presentations at the AASLD Liver Meeting 2019.

Barcelona Liver Bioservices (BLB) announced today the presentation of two communications at the annual meeting of the American Association for the Study of the Liver (AASLD), held in Boston, Massachusetts.

More
3 October, 2019

A nutraceutical rich in DHA improves portal hypertension in cirrhosis

Barcelona Liver Bioservices announced today the publication of the manuscript entitled “A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease” in the peer-reviewed journal Nutrients.

More
22 April, 2019

Depicting the underlying mechanisms of emricasan in advanced chronic liver disease

The study characterizes the effects, and underlying mechanisms, of the pan-caspase inhibitor emricasan on portal hypertension, fibrosis and liver cells phenotype in pre-clinical models of advanced cirrhosis. It integrates a variety of BLB’s experimental approaches, including the unique ExoLiver® platform, animal models of cirrhosis, and cellular secretome analysis, among others.

More
12 April, 2019

Barcelona Liver Bioservices announces poster presentations at the ILC-EASL annual meeting

Barcelona Liver Bioservices (BLB) announced today the presentation of two posters at the annual meeting of the European Association for the Study of the Liver (EASL), held in Vienna.

More
30 October, 2018

Barcelona Liver Bioservices announces collaboration with Inventiva

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Inventiva, a clinical stage biopharmaceutical company with expertise in fibrosis, oncology and orphan diseases.

More
25 June, 2018

Understanding the versatility of the ExoLiver® platform to study the pathobiology and new therapeutic options for liver diseases.

The study describes the benefits of using the ExoLiver® platform to simulate the human liver sinusoid on a chip.
View full article

More
22 February, 2018

Barcelona Liver Bioservices announces poster presentation at AEEH annual meeting

Barcelona Liver Bioservices (BLB) announced today the presentation of a poster introducing the BLB’s proprietary experimental model of nonalcoholic steatohepatitis (NASH) at the 42nd annual meeting of the Spanish Association for the Study of the Liver (AEEH), held in Madrid, Spain.

More
20 January, 2018

Barcelona Liver Bioservices enters into partnership with Gilead Sciences

Barcelona Liver Bioservices (BLB) announced today a non-exclusive partnership with the biopharmaceutical company Gilead Sciences to characterize the effects of novel chemical entities developed by Gilead for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).

More
9 January, 2018

Barcelona Liver Bioservices announces partnership with BrudyLab

Barcelona Liver Bioservices (BLB), CRO specialized in the design and development of pre-clinical research in hepatology, announced today a non-exclusive partnership with BrudyLab to explore Brudy’s lead compound DHA as novel therapeutic option for liver disease.

More
10 November, 2017

Barcelona Liver Bioservices announces collaboration with Conatus Pharmaceuticals

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Conatus Pharmaceuticals, biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.

More
2 November, 2017

Barcelona Liver Bioservices (BLB) starts operations

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

More